# psoriasis - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 31790
- Completion tokens: 10634
- Reasoning tokens: 0
- Total tokens: 42424
- API requests reported: 2
- Elapsed seconds: 139.201
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: OpenAI

---
## 1. Overall biological interpretation

The 100-gene differential signature is highly directional: **90 genes are upregulated and 10 are downregulated**, and all 100 have **FDR ≤ 0.01**. The dominant signal is a coordinated lesional-skin program involving:

- strong activation of **IL-36/IL-20-family inflammatory signaling**;
- induction of **keratinocyte antimicrobial defenses**;
- **epidermal hyperplasia, abnormal differentiation, and cornified-envelope remodeling**;
- recruitment or representation of **innate inflammatory leukocytes**;
- accompanying **lipid, protease, metabolic, and tissue-remodeling changes**.

This is biologically consistent with an inflamed psoriatic plaque rather than an isolated single-gene abnormality. For example, **IL36A** is upregulated by log2FC **11.373575** with FDR **1.6547601e-98**, while **DEFB4A** and **DEFB4B** are upregulated by log2FC **11.182922** and **11.030811**, respectively. The simultaneous induction of multiple cytokines, defensins, S100 proteins, cornification genes, and keratinocyte stress markers supports a coherent disease-state signature.

However, the very large effect sizes and uniformly extreme significance values warrant technical caution. They may reflect a strong biological contrast, but could also be amplified by tissue composition, sample preparation, batch effects, or comparison of highly inflamed lesions with relatively normal skin. **No independent-cohort statistical validation was performed**, and the external annotations do not constitute replication.

## 2. Core biological programs

### Program 1: IL-36/IL-20-family inflammatory signaling

- **Direction:** Upregulated in lesional skin.
- **Major supporting genes:** **IL36A** (log2FC 11.373575), **IL36G** (5.6840917), **IL36RN** (3.0051655), **IL19** (7.5795008), **IL20** (5.6674194), **IL26** (4.3612172), **IRAK2** (2.0828134), **TNIP3** (7.2788212), and **ZC3H12A** (3.8482629).
- **Relevant standardized pathways:**  
  - Reactome: **Interleukin-20 family signaling**  
  - KEGG: **IL-17 signaling pathway** and **cytokine–cytokine receptor interaction**  
  - GO: inflammatory and innate immune-response categories
- **Interpretation:** The coordinated increase in IL36A, IL36G, IL19, and IL20 indicates activation of an epithelial–immune cytokine circuit characteristic of inflamed skin. IL19 is annotated as signaling through IL20RA/IL20RB-containing receptor complexes, and STRING records support these receptor associations; these are receptor/signaling relationships, not direct physical interactions among all the cytokine genes. IL36RN is also increased, suggesting induction of an endogenous counter-regulatory component alongside inflammatory activation.
- **Evidence strength:** **Strong direct transcriptomic evidence** from multiple cytokine genes with very small FDR values, reinforced by Reactome and KEGG pathway annotations and disease literature.  
- **Limitations:** RNA expression does not establish cytokine secretion, receptor activation, cellular source, or causality. IL36RN induction may represent feedback rather than effective suppression. Pathway records can overlap in their underlying annotations and are not independent statistical validation.

### Program 2: Antimicrobial and innate epithelial defense

- **Direction:** Strongly upregulated.
- **Major supporting genes:** **DEFB4A** (log2FC 11.182922), **DEFB4B** (11.030811), **DEFB103A** (5.7579506), **DEFB103B** (5.7513848), **PI3** (9.2403801), **S100A7** (7.0947825), **S100A7A** (9.8326673), **S100A8** (7.7293672), **S100A12** (8.3288322), **TCN1** (8.0353765), and **SERPINB3/B4**.
- **Relevant standardized pathways:**  
  - GO: **Antimicrobial humoral response**  
  - GO: **response to lipopolysaccharide**  
  - KEGG: **Staphylococcus aureus infection**  
  - Related epithelial innate-defense and cytokine-response categories
- **Interpretation:** The defensin cluster, PI3, S100 proteins, and related secreted or epithelial defense genes indicate an activated antimicrobial barrier response. This program is consistent with the known inflammatory state of psoriatic epidermis, where keratinocytes produce antimicrobial peptides in response to cytokine stimulation.
- **Evidence strength:** **Strong direct evidence** from several independently annotated antimicrobial and inflammatory genes, with concordant pathway-level records.
- **Limitations:** The signature does not show whether microbial burden is increased, whether antimicrobial activity is functional, or whether some genes derive from infiltrating neutrophils or other myeloid cells. S100A8/S100A12 and TCN1 are particularly compatible with inflammatory-cell contributions, so this program should not be interpreted as purely keratinocyte intrinsic without cell-resolved data.

### Program 3: Epidermal hyperplasia, stress differentiation, and cornified-envelope remodeling

- **Direction:** Upregulated.
- **Major supporting genes:** **KRT6A** (log2FC 4.3025579), **SPRR2A/B/D/E/F/G**, **SPRR3**, **LCE3A** (8.2975962), **LCE3D** (5.3140542), **GJB2** (4.4194548), **GJB6** (3.01835), **SERPINB3** (6.7418584), **SERPINB4** (9.1181363), **TMPRSS11D** (7.7490328), **KLK13**, **PRSS27**, **RRM2**, and **CCNE1**.
- **Relevant standardized pathways:**  
  - Reactome: **Formation of the cornified envelope**  
  - GO: **epidermis development** and keratinocyte differentiation  
  - Hallmark-like interpretation: epithelial stress and proliferative remodeling
- **Interpretation:** The coordinated induction of small proline-rich proteins, late-cornified-envelope genes, keratins, proteases, and serpins indicates altered epidermal differentiation and barrier architecture. RRM2 and CCNE1 provide additional evidence for increased cell-cycle activity, although only two cell-cycle genes are represented in the supplied list.
- **Evidence strength:** **Strong direct multi-gene evidence**, supported by the supplied Reactome cornified-envelope annotation and GO epidermis-development annotation.  
- **Limitations:** Increased expression may reflect both altered transcription within keratinocytes and the greater abundance of epidermal cells in lesional tissue. The result does not distinguish regenerative hyperplasia from terminal differentiation defects or determine whether barrier function is improved or impaired.

### Program 4: Inflammatory-cell recruitment and lesional immune microenvironment

- **Direction:** Upregulated.
- **Major supporting genes:** **CXCL13** (log2FC 5.8933907), **CXCR2** (2.7005582), **GPR15LG** (5.5162775), **S100A8**, **S100A12**, **TCN1**, **PLBD1**, **HPSE**, **ADAP2**, and **CD274** (3.4395134).
- **Relevant standardized pathways:**  
  - KEGG: **cytokine–cytokine receptor interaction**  
  - GO: inflammatory response, leukocyte migration, and response to bacterial products  
  - Chemokine and extracellular-matrix remodeling categories
- **Interpretation:** This pattern is compatible with an altered immune microenvironment involving chemokine signaling, granulocyte-associated genes, and immune-regulatory ligand expression. CXCR2 and S100A8/S100A12 support a possible neutrophil-associated component, whereas CXCL13 may indicate organized or activated lymphoid chemotactic signaling. These observations should be treated as tissue-level associations rather than proof of a specific infiltrating-cell population.
- **Evidence strength:** **Moderate-to-strong direct evidence**, because several immune-associated genes move in the same direction; supported by pathway annotations and network records.
- **Limitations:** Bulk tissue expression cannot resolve whether the genes are expressed by keratinocytes, neutrophils, monocytes, dendritic cells, or lymphocytes. CXCL13 expression alone does not establish ectopic lymphoid organization or a specific T-cell response.

### Program 5: Lipid mediator, metabolic, and tissue-remodeling adaptation

- **Direction:** Predominantly upregulated, with selected downregulated metabolic or tissue-associated transcripts.
- **Major supporting genes:** **PLA2G4D** (log2FC 4.614801), **PLA2G4E** (2.4698712), **FABP5** (3.6445647), **KYNU** (4.4157874), **AKR1B10** (6.2653691), **AKR1B15** (5.2310671), **ABCG4** (4.7503317), **WNT5A** (2.5264849), and **HPSE** (2.9241399). Downregulated examples include **BTC** (−4.2989343), **CYP2W1** (−4.7044079), and **UGT3A2** (−4.5907749).
- **Relevant standardized pathways:** Lipid metabolism, phospholipid-mediated signaling, extracellular-matrix remodeling, and WNT-related tissue signaling; the supplied evidence does not provide a single definitive standardized pathway encompassing all of these genes.
- **Interpretation:** The PLA2G4D/E–FABP5 component is compatible with altered epidermal lipid mediator handling, while HPSE and WNT5A suggest tissue-remodeling and stromal/epithelial signaling. AKR1B10/15 and KYNU indicate metabolic adaptation but are less specific for psoriasis.
- **Evidence strength:** **Exploratory**, based mainly on coordinated expression and gene-function annotations.
- **Limitations:** This is a heterogeneous program, and formal pathway enrichment was not recomputed during synthesis. The downregulated genes have insufficient annotation context here to establish a unified suppressed pathway. Metabolic changes may reflect cell composition, treatment, or tissue handling rather than psoriasis-specific mechanism.

## 3. Key genes and interaction modules

The following candidates are prioritized for biological interpretability, not solely by fold change.

1. **IL36A–IL36G–IL36RN inflammatory module**  
   - **Direction:** IL36A +11.373575, IL36G +5.6840917, IL36RN +3.0051655; all FDR < 4 × 10⁻⁶² except IL36A/G with even smaller values.  
   - **Role:** Central inflammatory epithelial cytokine axis with simultaneous feedback inhibition.  
   - **Relationship type:** **Pathway co-membership and regulatory/feedback relationship**; IL36RN is an antagonist of IL-36 signaling. The supplied records do not establish a direct physical interaction between the cytokine proteins.

2. **IL19–IL20 cytokine signaling module**  
   - **Direction:** IL19 +7.5795008; IL20 +5.6674194.  
   - **Role:** IL-20-family epithelial–immune signaling and epidermal remodeling.  
   - **Relationship type:** **Pathway co-membership and receptor-mediated signaling**. STRING supports IL19 association with IL20RA and IL20RB; this does not mean IL19 and IL20 directly bind each other.

3. **DEFB4A–DEFB4B–DEFB103A/B antimicrobial module**  
   - **Direction:** All upregulated; DEFB4A +11.182922 and DEFB4B +11.030811.  
   - **Role:** Antimicrobial epithelial defense and IL-17-associated tissue response.  
   - **Relationship type:** **Gene-family/pathway co-membership and likely co-regulation**, not demonstrated direct protein interaction.

4. **S100A7/S100A7A–S100A8/S100A12 inflammatory module**  
   - **Direction:** S100A7 +7.0947825, S100A7A +9.8326673, S100A8 +7.7293672, S100A12 +8.3288322.  
   - **Role:** Epithelial stress, innate inflammation, and possible myeloid-cell contribution.  
   - **Relationship type:** **Co-expression and inflammatory pathway co-membership**. STRING records report network associations involving S100A7 and several selected genes, but the supplied evidence does not demonstrate direct physical interactions for the entire module.

5. **SPRR/LCE/KRT6A cornification module**  
   - **Direction:** Upregulated, including KRT6A +4.3025579, LCE3A +8.2975962, LCE3D +5.3140542, and multiple SPRR genes.  
   - **Role:** Cornified-envelope formation, epidermal stress differentiation, and barrier remodeling.  
   - **Relationship type:** **Structural/pathway co-membership and probable co-expression**. STRING links among SPRR and keratin genes are network evidence; they should not automatically be interpreted as direct physical binding.

6. **SERPINB3–SERPINB4 protease-regulation module**  
   - **Direction:** SERPINB3 +6.7418584; SERPINB4 +9.1181363.  
   - **Role:** Epithelial differentiation and regulation of proteolytic inflammatory processes.  
   - **Relationship type:** **Gene-family and functional co-membership**; STRING records also report associations with CTSG, but those records do not by themselves establish the direction or mechanism of interaction in psoriatic skin.

7. **CXCL13–CXCR2 inflammatory recruitment axis**  
   - **Direction:** CXCL13 +5.8933907; CXCR2 +2.7005582.  
   - **Role:** Chemotactic and inflammatory microenvironment.  
   - **Relationship type:** **Indirect chemokine/receptor relationship is putative in this dataset**; CXCR2 is not the canonical receptor for CXCL13, so these genes should not be presented as a direct ligand–receptor pair.

8. **PLA2G4D–PLA2G4E–FABP5 lipid-response module**  
   - **Direction:** PLA2G4D +4.614801, PLA2G4E +2.4698712, FABP5 +3.6445647.  
   - **Role:** Potential epidermal lipid mediator production and handling.  
   - **Relationship type:** **Metabolic/pathway co-membership and indirect biochemical relationship**, not direct physical interaction.

9. **CD274/PD-L1 immune-regulatory signal**  
   - **Direction:** CD274 +3.4395134.  
   - **Role:** Possible adaptive immune-regulatory response within inflamed tissue.  
   - **Relationship type:** **Regulatory ligand–receptor biology is plausible**, but the dataset does not identify the responding PD-1-positive cells or prove functional immune suppression.

10. **RRM2–CCNE1 proliferative module**  
    - **Direction:** RRM2 +2.7179913; CCNE1 +2.5573733.  
    - **Role:** Increased epidermal proliferation or cell-cycle activity.  
    - **Relationship type:** **Cell-cycle pathway co-membership and regulatory association**, not a demonstrated direct protein interaction in this analysis.

## 4. Validation priorities

### 1. IL-36/IL-20 signaling in lesional keratinocytes  
- **Classification:** Mechanistic hypothesis  
- **Why prioritize:** This is supported by several high-amplitude cytokine changes rather than one gene, including IL36A, IL36G, IL19, IL20, and IL36RN. Reactome and KEGG annotations provide biological plausibility.  
- **External evidence:** Literature and pathway records support IL-20-family signaling in epithelial inflammatory biology; the question-specific literature includes psoriasis biomarker work (PMID **40560938**), but no independent statistical result for this cohort was supplied.  
- **Next step:** Measure IL-36/IL-20 protein levels and receptor activation in lesional versus nonlesional keratinocytes; perturb IL36A/G or IL20 signaling in primary keratinocyte cultures or organotypic skin.  
- **Conclusion:** **Supported hypothesis**, not established causality.

### 2. Antimicrobial/keratinocyte inflammatory signature as a tissue biomarker  
- **Classification:** Biomarker  
- **Why prioritize:** DEFB4A/B, DEFB103A/B, PI3, S100A7/A7A, and cornification genes form a strong, biologically coherent tissue-level signature.  
- **External evidence:** GO antimicrobial-response and KEGG IL-17/infection annotations support plausibility, but these are contextual annotations rather than external validation.  
- **Next step:** Test a prespecified multi-gene score in an independent psoriasis cohort, including lesional, nonlesional, and healthy skin, and relate it to clinical severity and treatment response.  
- **Conclusion:** **Supported hypothesis** for tissue classification; clinical utility is currently **insufficient evidence**.

### 3. Separate keratinocyte-intrinsic activation from immune-cell composition  
- **Classification:** Confounding or composition check  
- **Why prioritize:** The combination of epidermal genes with S100A8, S100A12, TCN1, PLBD1, and CXCR2 could reflect both epithelial activation and infiltrating myeloid cells.  
- **External evidence:** Tissue-expression and disease annotations support both possibilities, but bulk RNA data cannot resolve cellular origin.  
- **Next step:** Perform single-cell or spatial transcriptomics, or validate with immunohistochemistry and cell-type deconvolution using independently justified marker sets.  
- **Conclusion:** **Established limitation** and a high-priority interpretive check.

### 4. PLA2G4D/E–FABP5 lipid mediator remodeling  
- **Classification:** Mechanistic hypothesis  
- **Why prioritize:** Multiple lipid-associated genes are upregulated, suggesting more than an isolated annotation, but the program is less specific than the cytokine and barrier programs.  
- **External evidence:** Functional annotations and tissue-expression records support a plausible epidermal lipid role; no independent psoriasis statistic or direct metabolomic confirmation is available.  
- **Next step:** Profile lesional lipid mediators and test PLA2G4D/E or FABP5 perturbation in keratinocytes, ideally with barrier-function and inflammatory readouts.  
- **Conclusion:** **Exploratory hypothesis**.

### 5. SPRR/LCE/KRT6A structural network and epidermal remodeling  
- **Classification:** Interaction / network hypothesis  
- **Why prioritize:** Multiple cornification genes are strongly upregulated, and STRING records indicate network associations among SPRR, KRT6A, and LCE genes.  
- **External evidence:** Reactome cornified-envelope annotation and protein/network records support functional connectivity. These records indicate **network association or pathway co-membership**, not necessarily direct physical interactions.  
- **Next step:** Confirm spatial co-localization and protein-level changes, then test whether perturbing selected structural regulators alters barrier integrity, differentiation, or cytokine responses.  
- **Conclusion:** **Supported hypothesis** at the program level; causal network hierarchy remains unestablished.

## 5. Limitations and alternative explanations

1. **Tissue and cell-composition effects:** Lesional skin contains expanded or activated keratinocytes and infiltrating immune cells. This could explain part of the S100A8/S100A12, TCN1, PLBD1, CXCR2, and cytokine signal. Single-cell, spatial, or protein-level validation is needed.

2. **Large effect sizes and uniformly extreme significance:** All 100 genes meet FDR ≤ 0.01, with 90 upregulated. This may represent a genuine strong lesion-versus-normal contrast, but batch, platform, normalization, sample quality, or unusually separated biological groups should be audited. Sample size, variance estimates, and experimental design were not supplied.

3. **Disease severity and treatment exposure:** Lesion activity, chronicity, recent topical or systemic treatment, and anatomical site can strongly influence cytokine, antimicrobial, and epidermal programs. These variables should be recorded and incorporated into replication models.

4. **Bulk tissue cannot establish causation:** Increased IL36A, IL20, defensins, CD274, or WNT5A may be consequences, amplifiers, or compensatory responses rather than initiating drivers. Perturbation experiments and longitudinal treatment studies are required.

5. **External evidence is contextual, not replicated statistics:** Reactome, GO, KEGG, STRING, tissue, genetic, therapeutic, and literature records support plausibility, but may overlap in their source publications or prediction models. **External statistical validation was not performed**, so the direction, FDR, and effect sizes remain demonstrated only for the supplied cohort.

Overall, the most defensible interpretation is that these lesions exhibit a tightly coordinated **IL-36/IL-20-associated inflammatory epidermal state with antimicrobial activation, cornification remodeling, and an immune-cell component**, while the causal hierarchy and clinical generalizability remain to be established.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=5, external claims checked=0, external mismatches=0, status=passed.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
